TransMedics Group, Inc. Earnings Recaps
TransMedics reported record third-quarter revenue of approximately $203 million, up 41% year over year, and the stock rose 27.9% after earnings. Growth was driven by Liver and Heart market-share gains and transplant services; the company said ENHANCE Part B and DENOVO have not yet contributed.
Key takeaways
- Transplant product revenue was $113 million, up approximately 29% year over year; transplant service revenue was roughly $79 million, up approximately 44%.
- OCS Liver and Heart case volumes grew year over year and sequentially, modestly exceeding the prior-quarter record despite typical seasonality; U.S. disease donor volume was down 6%.
- TransMedics’ logistics revenue was approximately $41 million, up 50%; its fleet handled about 86% of NOP missions requiring air transport, in line with the prior quarter.
- The company ended the quarter with approximately $493 million in cash and said it generated approximately $20 million in cash and expanded product and service margins.
- FDA approved protocol amendments for ENHANCE Heart Part B and DENOVO Lung, both expected to be catalysts beginning in Q1 2027; the trials could open access to additional heart and lung transplant cases.
Shares fell 6.2% as investors reacted negatively to cautious growth outlook and heavy investment weighing on near-term operating leverage despite solid revenue gains.
Key takeaways
- Total revenue reached approximately $190 million, up 21% year-over-year and 9% sequentially, driven by broad-based growth across product and service lines.
- Transplant product revenue increased 16% year-over-year to $111 million, with liver cases up 28% and heart cases up 6% annually.
- Logistics revenue, a key differentiator, grew 39% year-over-year to $41 million, reflecting expanded air transport coverage and improved operational efficiency.
- Adjusted income from operations stood at roughly $25.8 million (14% margin), but management emphasized prioritizing growth investments over near-term leverage.
- The company doubled down on expansion with a strategic investment in PAD Aviation, aiming to build a European transplant logistics network, signaling further near-term capital deployment.
Shares dropped 24.9% following the earnings release as investors were clearly disappointed by the cautious outlook and enrollment delays in critical clinical programs, which suggest a deceleration in near-term growth drivers despite solid revenue growth.
Key takeaways
- Total revenue grew 21% year-over-year to $174 million, with U.S. transplant product revenue up 22% and OUS transplant revenue increasing 39%.
- Adjusted operating profit reached $18.1 million, or 10.4% of revenue, reflecting ongoing heavy investment in growth initiatives.
- Enrollment delays in the ENHANCE and DENOVO clinical programs due to competitive reactions have postponed anticipated contributions from these key cardiothoracic growth drivers.
- Introduction of the CHOPS device aims to address clinical trial enrollment challenges and expand the product portfolio, but regulatory clearance is still pending.
- Despite operational progress, the market reacted negatively, signaling concerns over near-term growth sustainability and cautious outlook from management.
TransMedics achieved robust Q3 2025 results, with total revenue up 32.2% year-over-year to approximately $144 million, driven by strong growth across all organ segments despite typical seasonal slowdowns.
Key takeaways
- Operating profit soared to $23.3 million, representing over 16% of total revenue, compared to just 4% in Q3 2024.
- Transplant logistics service revenue grew 35% year-over-year, with 21 aircraft currently operational to enhance mission coverage.
- Anticipation builds for the upcoming ENHANCE Heart and DENOVO Lung clinical trials, expected to drive future adoption of OCS technology.
- Expansion into international markets is underway, with plans to launch the first OUS NOP program in Italy and establish strategic regional hubs.